Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of March 2026, specifically reporting a transaction notification dated March 4, 2026. GSK plc is a global biopharma company headquartered in London, England.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is a transaction notification regarding insider trading activity rather than a financial results report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses a specific acquisition of securities by a Person Discharging Managerial Responsibilities (PDMR).
Transaction Details and Commentary
- Transaction Type: Acquisition of American Depositary Shares (ADS) under the GSK pension plan.
- Individual: Diana Conrad, Chief People Officer.
- Date: March 2, 2026.
- Volume: 11,569 ADS.
- Price: $58.6439 per ADS.
- Exchange: New York Stock Exchange (XNYS).
Management commentary, guidance, outlook, risks, and contingencies are not included in this filing.
Investor Verification Points
- Verify the total number of ADS held by Diana Conrad post-transaction against prior holdings.
- Confirm the current market price of GSK ADS relative to the $58.6439 transaction price.
- Review the GSK pension plan rules regarding the timing and volume of such acquisitions.